Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study.
José R González PorrasMoncef Belhassen-GarcíaAmparo López BernúsLuis Mario Vaquero-RonceroBeatriz RodriguezCristina CarbonellRaul AzibeiroAlberto Hernandez-SanchezJose Ignacio Martin-GonzalezJuan Miguel ManriqueGloria Alonso-ClaudioFelipe Alvarez-NaviaJose Ignacio Madruga-MartinRonald Paul Macias-CasanovaJorge García-CriadoFrancisco LozanoJose Carlos MoyanoMiguel Vicente Sanchez-HernandezVíctor SagredoRafael BorrásJosé Maria BastidaGuillermo Hernández-PérezAntonio-Javier ChamorroMiguel MarcosJosé Ángel Martín-OterinoPublished in: Sao Paulo medical journal = Revista paulista de medicina (2021)
This observational study showed that LMWH administered at the time of admission was associated with lower mortality among unselected adult COVID-19 inpatients. The magnitude of the benefit may have been greatest for the intermediate-dose subgroup. Randomized controlled trials to assess the benefit of heparin within different therapeutic regimes for COVID-19 patients are required.